Inflammatory Bowel Disease patients requiring surgery can be treated in referral centres regardless of the COVID-19 status of the hospital: results of a multicentric European study during the first COVID-19 outbreak (COVIBD-Surg).
COVID-19
Inflammatory bowel disease
Surgery
Journal
Updates in surgery
ISSN: 2038-3312
Titre abrégé: Updates Surg
Pays: Italy
ID NLM: 101539818
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
30
04
2021
accepted:
17
06
2021
pubmed:
28
6
2021
medline:
16
10
2021
entrez:
27
6
2021
Statut:
ppublish
Résumé
Outcomes of inflammatory bowel disease (IBD) patients requiring surgery during the outbreak of Coronavirus disease 19 (COVID-19) are unknown. Aim of this study was to analyse the outcomes depending on the COVID-19 status of the centre. Patients undergoing surgery in six COVID-19 treatment and one COVID-free hospitals (five countries) during the first COVID-19 peak were included. Variables associated with risk of moderate-to-severe complications were identified using logistic regression analysis. A total of 91 patients with Crohn's disease (54, 59.3%) or ulcerative colitis (37, 40.7%), 66 (72.5%) had surgery in one of the COVID-19-treatment hospitals, while 25 (27.5%) in the COVID-19-free centre. More COVID-19-treatment patients required urgent surgery (48.4% vs. 24%, p = 0.035), did not discontinue biologic therapy (15.1% vs. 0%, p = 0.039), underwent surgery without a SARS-CoV-2 test (19.7% vs. 0%, p = 0.0033), and required intensive care admission (10.6% vs. 0%, p = 0.032). Three patients (4.6%) had a SARS-CoV-2 infection postoperatively. Postoperative complications were associated with the use of steroids at surgery (Odds ratio [OR] = 4.10, 95% CI 1.14-15.3, p = 0.03), presence of comorbidities (OR = 3.33, 95% CI 1.08-11, p = 0.035), and Crohn's disease (vs. ulcerative colitis, OR = 3.82, 95% CI 1.14-15.4, p = 0.028). IBD patients can undergo surgery regardless of the COVID-19 status of the referral centre. The risk of SARS-CoV-2 infection should be taken into account.
Identifiants
pubmed: 34176073
doi: 10.1007/s13304-021-01119-y
pii: 10.1007/s13304-021-01119-y
pmc: PMC8235901
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1811-1818Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2021. Italian Society of Surgery (SIC).
Références
Onder G, Rezza G, Brusaferro S (2020) Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA 323:1775–1776
pubmed: 32203977
World Health Organization Coronavirus disease 2019 (COVID–19): situation report—67. March 31, 2020. https://www.who.int/docs/default–source/coronaviruse/situation–reports/20200407–sitrep–78–covid–19.pdf?sfvrsn=bc43e1b_2 . Accessed 30 Jan 2021
COVIDSurg Collaborative (2020) Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study. Lancet 396:27–38
doi: 10.1016/S0140-6736(20)32275-3
COVIDSurg Collaborative (2020) Outcomes from elective colorectal cancer surgery during the SARS-CoV-2 pandemic. Colorectal Dis. https://doi.org/10.1111/codi.15431
doi: 10.1111/codi.15431
pmcid: 7753519
Tinsley A, Navabi S, Williams ED, Liu G, Kong L, Coates MD, Clarke K (2019) Increased risk of influenza and influenza-related complications among 140,480 patients with inflammatory bowel disease. Inflamm Bowel Dis 25:369–376
doi: 10.1093/ibd/izy243
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42:377–381
doi: 10.1016/j.jbi.2008.08.010
Magro F, Rahier JF, Abreu C, MacMahon E, Hart A, van der Woude CJ, Gordon H, Adamina M, Viget N, Vavricka S, Kucharzik T, Leone S, Siegmund B, Danese S, Peyrin-Biroulet L (2020) Inflammatory bowel disease management during the COVID-19 outbreak: the ten do’s and don’ts from the ECCO-COVID taskforce. J Crohns Colitis 14(Suppl_3):S798–S806
doi: 10.1093/ecco-jcc/jjaa160
Kennedy NA, Jones GR, Lamb CA, Appleby R, Arnott I, Beattie RM, Bloom S, Brooks AJ, Cooney R, Dart RJ, Edwards C, Fraser A, Gaya DR, Ghosh S, Greveson K, Hansen R, Hart A, Hawthorne AB, Hayee B, Limdi JK, Murray CD, Parkes GC, Parkes M, Patel K, Pollok RC, Powell N, Probert CS, Raine T, Sebastian S, Selinger C, Smith PJ, Stansfield C, Younge L, Lindsay JO, Irving PM, Lees CW (2020) British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic. Gut 6:984–990
doi: 10.1136/gutjnl-2020-321244
Remzi FH, Panis Y, Spinelli A, Kotze PG, Mantzaris G, Söderholm JD, d’Hoore A, Bemelman WA, Yamamoto T, Pemberton JH, Tiret E, Øresland T, Fleshner P (2020) International organization for the study of IBD recommendations for surgery in patients with IBD during the coronavirus disease 2019 pandemic. Dis Colon Rectum 63:870–873
doi: 10.1097/DCR.0000000000001718
Allez M, Fleshner P, Gearry R, Lakatos PL, Rubin DT (2020) Care of the patient with IBD requiring hospitalisation during the COVID-19 pandemic. J Crohns Colitis 14(Suppl_3):S774–S779. https://doi.org/10.1093/ecco-jcc/jjaa150
doi: 10.1093/ecco-jcc/jjaa150
pubmed: 32722757
D’Amico F, Peyrin-Biroulet L, Danese S (2020) Inflammatory bowel diseases and COVID-19: the invisible enemy. Gastroenterology 158:2302–2304
doi: 10.1053/j.gastro.2020.04.032
Wisniewski A, Kirchgesner J, Seksik P, Landman C, Bourrier A, Nion-Larmurier I, Marteau P, Cosnes J, Sokol H, Beaugerie L, the Saint-Antoine IBD network (2020) Increased incidence of systemic serious viral infections in patients with inflammatory bowel disease associates with active disease and use of thiopurines. United Eur Gastroenterol J 8:303–313
doi: 10.1177/2050640619889763
Garg M, Royce SG, Tikellis C, Shallue C, Batu D, Velkoska E, Burrell LM, Patel SK, Beswick L, Jackson A, Britto K, Lukies M, Sluka P, Wardan H, Hirokawa Y, Tan CW, Faux M, Burgess AW, Hosking P, Monagle S, Thomas M, Gibson PR, Lubel J (2020) Imbalance of the renin-angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target? Gut 69:841–851
doi: 10.1136/gutjnl-2019-318512
Taxonera C, Sagastagoitia I, Alba C, Mañas N, Olivares D, Rey E (2020) 2019 Novel coronavirus disease (COVID-19) in patients with inflammatory bowel diseases. Aliment Pharmacol Ther 52:276–283
doi: 10.1111/apt.15804
Allocca M, Fiorino G, Zallot C, Furfaro F, Gilardi D, Radice S, Danese S, Peyrin-Biroulet L (2020) Incidence and patterns of COVID-19 among inflammatory bowel disease patients from the Nancy and Milan cohorts. Clin Gastroenterol Hepatol 18:2134–2135
doi: 10.1016/j.cgh.2020.04.071
Bezzio C, Saibeni S, Variola A, Allocca M, Massari A, Gerardi V, Casini V, Ricci C, Zingone F, Amato A, Caprioli F, Lenti MV, Viganò C, Ascolani M, Bossa F, Castiglione F, Cortelezzi C, Grossi L, Milla M, Morganti D, Pastorelli L, Ribaldone DG, Sartini A, Soriano A, Manes G, Danese S, Fantini MC, Armuzzi A, Daperno M, Fiorino G, Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) (2020) Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. Gut 69:1213–1217
doi: 10.1136/gutjnl-2020-321411
Brenner EJ, Ungaro RC, Gearry RB, Kaplan GG, Kissous-Hunt M, Lewis JD, Ng SC, Rahier JF, Reinisch W, Ruemmele FM, Steinwurz F, Underwood FE, Zhang X, Colombel JF, Kappelman MD (2020) Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry. Gastroenterology 159:481–491
doi: 10.1053/j.gastro.2020.05.032
Rizzello F, Calabrese C, Salice M, Calandrini L, Privitera H, Melotti L, Peruzzi G, Dussias N, Belluzzi A, Scaioli E, Decorato A, Siniscalchi A, Filippone E, Laureti S, Rottoli M, Poggioli G, Gionchetti P (2020) COVID-19 in IBD: The experience of a single tertiary IBD center. Dig Liver Dis 53:271–276
doi: 10.1016/j.dld.2020.12.012
Lan N, Zhi M, Chen Y, Wu X, Lan P, Kiran RP, Shen B (2020) Experience of hospital admission and surgery during the COVID-19 pandemic: a survey of IBD patients. J Gastrointest Surg 3:1–5
Botti F, Mazza S, Costa S, Farina E, Baldari L, Prati M (2020) Urgent surgery for inflammatory bowel diseases during the COVID-19 outbreak in a high incidence area—experience from a high-volume centre. Dig Liver Dis 52:1241–1243
doi: 10.1016/j.dld.2020.08.039
Urgent Intercollegiate General Surgery Guidance on COVID-19, posted on 25 March 2020. https://www.acpgbi.org.uk/news/urgent-intercollegiate-general-surgery-guidance-on-covid-19/ . Accessed 1 Feb 2021
United Kingdom National Health System: advice on maintaining cancer treatment during the COVID-19 response, 30 March 2020. https://www.bopa.org.uk/wp-content/uploads/2020/03/C0119-_Maintaining-cancer-services-_-letter-to-trusts.pdf . Accessed 1 Feb 2021